tickrz reports
  
tickrz rank
C
AbbVie Inc (ABBV)
Healthcare | Drug Manufacturers - Major
CEO: Richard A. Gonzalez
Employees: 28000
abbvie.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank319Dividend Rank241
Moat Rank117Financial Strength Rank379
Growth Rank250Momentum Rank321
DIVIDEND ANALYSIS
Dividend Yield3.69%
Payout Ratio60.54%
3 yr Dividend Growth13.67%
VALUATION RATIOS
P/E Ratio16.66x
P/B Ratio21.03x
P/S Ratio4.01x
EV/EBITDA Ratio12.73x
FINANCIAL STRENGTH
Piotroski F-Score5
Debt-to-Equity739%
Interest Coverage0x
MOAT
ROE130.9%
ROIC23.99%
Net Margin23.1%
GROWTH
5 yr EPS Growth10.82%
5 yr SPS Growth8.01%
5 yr BPS Growth-17.75%
AbbVie Inc's return on equity of 130.9% speaks to its strong moat
 tickrz summary
AbbVie Inc receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. AbbVie Inc's valuation score is comprised of a P/E ratio of 16.7x, a P/B ratio of 21x, a P/S ratio of 4x, and an EV/EBITDA ratio of 12.7x. AbbVie Inc ranks 319 out of the S&P 500 constituents on valuation--a relatively weak score.AbbVie Inc ranks 293 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, AbbVie Inc is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. AbbVie Inc appears to have a durable competitive advantage within the Healthcare sector. AbbVie Inc has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 0x, a debt/equity ratio of 739% and a Moat Rank of 117 translate to a weak Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 7.03% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 321. Based on its 12 month stock performance, AbbVie Inc will not appeal to momentum investors.

 yield
 value + yield
Shares currently yield 3.69%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, AbbVie Inc ranks 241 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 10.8% 5 year annualized EPS growth, 8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -17.7% combine to produce this average score.

AbbVie Inc (ABBV)
Healthcare | Drug Manufacturers - Major
CEO: Richard A. Gonzalez
Employees: 28000
abbvie.com


tickrz rank
C

VALUATION RATIOS
P/E Ratio16.66x
P/B Ratio21.03x
P/S Ratio4.01x
EV/EBITDA Ratio12.73x
DIVIDEND ANALYSIS
Dividend Yield3.69%
Payout Ratio60.54%
3 yr Dividend Growth13.67%
FINANCIAL STRENGTH
Piotroski F-Score5
Debt-to-Equity739%
Interest Coverage0x
MOAT
ROE130.9%
ROIC23.99%
Net Margin23.1%
GROWTH
5 yr EPS Growth10.82%
5 yr SPS Growth8.01%
5 yr BPS Growth-17.75%

TICKRZ RANK
AbbVie Inc receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. AbbVie Inc's valuation score is comprised of a P/E ratio of 16.7x, a P/B ratio of 21x, a P/S ratio of 4x, and an EV/EBITDA ratio of 12.7x. AbbVie Inc ranks 319 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
AbbVie Inc ranks 293 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, AbbVie Inc is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. AbbVie Inc appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
AbbVie Inc has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 0x, a debt/equity ratio of 739% and a Moat Rank of 117 translate to a weak Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 7.03% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 321. Based on its 12 month stock performance, AbbVie Inc will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 3.69%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, AbbVie Inc ranks 241 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 10.8% 5 year annualized EPS growth, 8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -17.7% combine to produce this average score.